A revolution in the efficacy of inhaled drugs
Aquilon Pharma aims to play a disruptive role in the next generation formulation technology for inhaled medication by improving the efficacy of inhaled drug.
About us
With its scientific roots in Liège University, Aquilon Pharma is an independent PharmaTech company, specialized in the improvement of the efficacy of drugs, administered through inhalation.
Aquilon in numbers
dedicated team members
innovative products
€-Million Aquilon valuation
achieved clinical trials
ongoing clinical trials
Our technology
HP-Betadex is one of the selected functional excipients for inhalation. This excipient technology improves both the pharmacology and the lung deposition of existing drugs.
Our portfolio
Aquilon Pharma focuses on asthma, COPD and Nasal. Our formulations are compatible with all devices.
Our latest news
Aquilon Pharma has signed a purchase order for ISAB’s high-precision R&D system PreciseInhale®
Innovative inhalation pharmaceutical technology company Aquilon Pharma, based in Belgium, has signed a purchase order for ISAB’s high-precision R&D system...
Aquilon Pharma launches a Phase II clinical trial for Covid19 patients in the acute respiratory phase
Aquilon Pharma is a spin-off from the University of Liège set up at the end of 2013, specializing in the...
New laboratories
Canal Z « Aquilon Pharma inaugure son nouveau laboratoire » The 31/01/2022 by Maxime Simon. L’Echo « Aquilon démarre une...
Collective representative office in Texas
With the support of Awex, Revatis, Brevo Motors, Aquilon Pharma and Taipro set up a joint representative office in Texas....
News Release
Aquilon Pharmaceuticals has passed an important milestone in the development of its first treatment AQ001S, based on a technological complex...
Board reshuffle at Aquilon Pharmaceuticals
Following a decision, taken during the September Board meeting, Mr Paul Maes handed over the role of Executive Chairman to...
Aquilon and partners cross the mid-term milestone for Aeronext
Aquilon Pharma, together with its partners, recently reached an important milestone (the “go/no go milestone” on the research part) for...
Aquilon proves the high potential of HP-Betadex in Dry Powder formulation
The BioWin-funded Aeronext research project has reached its mid-term milestone, confirming the clinical and technological potential of HP-Betadex formulations for...
A highly experienced team
The Aquilon Pharma drug development team is working on the technical aspects, such as pharmacology, toxicology, clinical studies, pharmaceutical development, etc.
Our partners
Would you like to be a partner of Aquilon Pharma?
Follow us
Stay up to date by following our media channels for our very latest news
Contact us
Do you have a question? Let's get in touch.